Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MTI Onyx V. Aneurysm Coil Trial Protocol Revisited; PMA On Track For 2004

This article was originally published in The Gray Sheet

Executive Summary

Micro Therapeutics' revised inclusion criteria for its U.S. pivotal trial comparing the Onyx LES liquid embolic system with Boston Scientific's GDC Ultrasoft coil to treat brain aneurysms will delay PMA filing by three fiscal quarters, MTI estimates
Advertisement

Related Content

MTI, FDA Revisit Onyx Aneurysm Trial Protocol: Enrollment Struggles Cited
MTI, FDA Revisit Onyx Aneurysm Trial Protocol: Enrollment Struggles Cited
FDA Neurology Panel Will Review MTI Onyx PMA Based On Coil Comparison
FDA Neurology Panel Will Review MTI Onyx PMA Based On Coil Comparison
Micro Therapeutics Fills Out Aneurysm Pipeline With Dendron Embolic Coils
Micro Therapeutics Fills Out Aneurysm Pipeline With Dendron Embolic Coils
MicroVention HydroCoil Cerebral Aneurysm Postmarket Study Set To Launch
MicroVention HydroCoil Cerebral Aneurysm Postmarket Study Set To Launch
Micro Therapeutics, Inc.
Advertisement
UsernamePublicRestriction

Register

MT017031

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel